Skip to main content
HR 5556 102th Congress House Health Department of Health and Human Services Drugs Executive reorganization Patents Prescription pricing Restrictive trade practices

Patented Medicine Prices Review Board Act of 1992

Introduced: July 2, 1992 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 102nd Congress ended
It never became law before the 102nd Congress (1991–1992) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 30, 1992
Referred to the Subcommittee on Intellectual Property and Judicial Administration.
Jul 24, 1992
Referred to the Subcommittee on Health and the Environment.
Jul 2, 1992
Referred to the House Committee on Judiciary.
Jul 2, 1992
Referred to the House Committee on Energy and Commerce.
Jul 2, 1992
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Patented Medicine Prices Review Board Act of 1992 - Establishes in the Food and Drug Administration the Patented Medicine Prices Review Board. Directs the Board to require each patentee of a prescription drug to provide information annually on: (1) the type of prescription drug sold by the patentee; (2) the price at which the drug is being sold in the United States; and (3) the costs of producing and marketing the drug in the United States.

Requires the Board to decrease the length of a patent term for a prescription drug if the patentee of such drug charges an excessive price for its use.

Allows the Board to increase the patent term for a prescription if the patentee has not charged an excessive price for such drug during a five-year period and provides assurances that it will not charge an excessive price during the extension of the term.

Requires the Board to report annually to each Federal agency that dispenses or makes payments for the dispensing of prescription drugs on: (1) a list of prescription drugs sold at excessive prices; (2) recommendations against dispensing or making payments for such drugs; and (3) recommendations to substitute the drug with a similar prescription drug which is not sold at an excessive price.

Requires the Board to report annually to the Congress describing its activities.

What's happening now July 30, 1992

Referred to the Subcommittee on Intellectual Property and Judicial Administration.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Independent 1
I
Sanders, Bernard
Vermont · Sep 17, 1992
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5556: Patented Medicine Prices Review Board Act of 1992. 102nd Congress. Open America. https://openamerica.io/bill/102-HR-5556/
MLA
"H.R. 5556: Patented Medicine Prices Review Board Act of 1992." 102nd Congress, 2026, Open America, https://openamerica.io/bill/102-HR-5556/.
Bluebook (legal)
H.R. 5556, 102nd Cong. (2026), https://openamerica.io/bill/102-HR-5556/.
Markdown link
[H.R. 5556: Patented Medicine Prices Review Board Act of 1992](https://openamerica.io/bill/102-HR-5556/)
Report a problem